DrugsNews.net

Drugs Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Gastroenterologia.net

Search results for "Harvoni"

The European Commission has granted marketing authorization for Harvoni ( Ledipasvir 90 mg / Sofosbuvir 400 mg ), the first once-daily single tablet regimen to treat the majority of chronic hepatitis ...


The FDA ( Food and Drug Administration ) has approved Viekira Pak ( Ombitasvir, Paritaprevir and Ritonavir tablets co-packaged with Dasabuvir tablets ) to treat patients with chronic hepatitis C virus ...


The FDA ( Food and Drug Administration ) has approved additional indications for Harvoni ( Ledipasvir / Sofosbuvir ) for use in chronic hepatitis C patients with advanced liver disease. Harvoni in c ...


The European Commission has granted marketing authorization for Epclusa ( Sofosbuvir 400 mg / Velpatasvir 100 mg ), the first pan-genotypic, single tablet regimen for the treatment of adults with geno ...


The European Commission ( EC ) has granted marketing authorization for Vosevi ( Sofosbuvir 400mg / Velpatasvir 100mg / Voxilaprevir 100mg ), as a once-daily single tablet regimen for the treatment of ...